AU2006341375B2 - Amylin and amylin agonists for treating psychiatric diseases and disorders - Google Patents

Amylin and amylin agonists for treating psychiatric diseases and disorders Download PDF

Info

Publication number
AU2006341375B2
AU2006341375B2 AU2006341375A AU2006341375A AU2006341375B2 AU 2006341375 B2 AU2006341375 B2 AU 2006341375B2 AU 2006341375 A AU2006341375 A AU 2006341375A AU 2006341375 A AU2006341375 A AU 2006341375A AU 2006341375 B2 AU2006341375 B2 AU 2006341375B2
Authority
AU
Australia
Prior art keywords
seq
amylin
xaa
hamylin
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006341375A
Other languages
English (en)
Other versions
AU2006341375A1 (en
AU2006341375A2 (en
Inventor
Michael Hanley
Kevin D. Laugero
Christine Mack
David G. Parkes
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Publication of AU2006341375A1 publication Critical patent/AU2006341375A1/en
Publication of AU2006341375A2 publication Critical patent/AU2006341375A2/en
Assigned to AMYLIN PHARMACEUTICALS, LLC, ASTRA ZENECA PHARMACEUTICALS LP reassignment AMYLIN PHARMACEUTICALS, LLC Request for Assignment Assignors: AMYLIN PHARMACEUTICALS, INC.
Assigned to ASTRA ZENECA PHARMACEUTICALS LP reassignment ASTRA ZENECA PHARMACEUTICALS LP Request for Assignment Assignors: AMYLIN PHARMACEUTICALS, LLC, ASTRA ZENECA PHARMACEUTICALS LP
Application granted granted Critical
Publication of AU2006341375B2 publication Critical patent/AU2006341375B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2006341375A 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders Ceased AU2006341375B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/US2006/012601 2006-03-31
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (3)

Publication Number Publication Date
AU2006341375A1 AU2006341375A1 (en) 2007-10-11
AU2006341375A2 AU2006341375A2 (en) 2009-09-24
AU2006341375B2 true AU2006341375B2 (en) 2013-03-21

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006341375A Ceased AU2006341375B2 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Country Status (7)

Country Link
EP (1) EP2010208A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009538824A (cg-RX-API-DMAC7.html)
KR (1) KR20080106950A (cg-RX-API-DMAC7.html)
AU (1) AU2006341375B2 (cg-RX-API-DMAC7.html)
CA (1) CA2647568A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012666A (cg-RX-API-DMAC7.html)
WO (1) WO2007114838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー/エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2013511287A (ja) 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686411A (en) * 1991-03-08 1997-11-11 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US20050197287A1 (en) * 2004-03-04 2005-09-08 Mack Christine M. Methods for affecting body composition
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686411A (en) * 1991-03-08 1997-11-11 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US20050197287A1 (en) * 2004-03-04 2005-09-08 Mack Christine M. Methods for affecting body composition
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Flood et al (1992) Peptides, 13(3):577-580 *
Moreley et al (1995) Canadian Journal of Physiology and Pharmacology, 73:1042-1046 *

Also Published As

Publication number Publication date
CA2647568A1 (en) 2007-10-11
WO2007114838A1 (en) 2007-10-11
AU2006341375A1 (en) 2007-10-11
MX2008012666A (es) 2008-10-13
EP2010208A1 (en) 2009-01-07
JP2009538824A (ja) 2009-11-12
KR20080106950A (ko) 2008-12-09
AU2006341375A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
US7671023B2 (en) Amylin agonist for treating depression, anxiety disorder and schizophrenia
US7399744B2 (en) Methods for affecting body composition
US7910548B2 (en) Methods for treating obesity
US7485620B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2006341375A2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
EP0964695B1 (en) Methods and compositions for treating pain
EP2120985B1 (en) FN-38 peptides for use in the treatment of psychotic and anxiety disorders
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
JP2019525931A (ja) ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
CA2674186A1 (en) Use of somatostatin analogs in cluster headache

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO DELETE DIVISIONAL AU 2006230602

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2009

PC1 Assignment before grant (sect. 113)

Owner name: ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUT

Free format text: FORMER APPLICANT(S): AMYLIN PHARMACEUTICALS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: ASTRA ZENECA PHARMACEUTICALS LP

Free format text: FORMER APPLICANT(S): ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS, LLC

TH Corrigenda

Free format text: IN VOL 27 , NO 5 , PAGE(S) 692 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2006 UNDERTHE NAME ASTRA ZENECA PHARMACEUTICALS LP, APPLICATION NO. 2006341375, UNDER INID (71), CORRECT THE NAME TO ASTRAZENECA PHARMACEUTICALS AND AMYLIN PHARMACEUTICALS, LLC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired